Autoimmune diseases diagnosis are the diseases in which the production of antibodies takes place in the body which attacks and destroys own healthy cells in the body. These include Crohn's disease, rheumatoid arthritis, Hashimoto’s disease, multiple sclerosis, Grave’s disease, psoriasis, coeliac disease, type 1 diabetes, lupus and inflammatory bowel syndrome, and are diagnosed by immunological tests. The main test types of autoimmune disease diagnosis are routine laboratory tests, autoantibodies tests, immunologic tests, and other tests. Autoantibody tests are used to aid in the diagnosis of autoimmune diseases. The different products include consumables and assay kits, instruments and are used by various sectors such as clinical laboratories, hospitals, and others. The autoimmune disease diagnosis market research report is one of a series of new reports from The Business Research Company that provides autoimmune disease diagnosis market statistics, including autoimmune disease diagnosis industry global market size, regional shares, competitors with a autoimmune disease diagnosis market share, detailed autoimmune disease diagnosis market segments, market trends and opportunities, and any further data you may need to thrive in the autoimmune disease diagnosis industry. This autoimmune disease diagnosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global autoimmune disease diagnosis market size will grow from $5.15 billion in 2022 to $5.56 billion in 2023 at a compound annual growth rate (CAGR) of 7.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global autoimmune disease diagnosis market size is expected to grow to $7.55 billion in 2027 at a CAGR of 8.0%. A high incidence of autoimmune diseases contributed to the growth of the autoimmune disease diagnosis market. According to the Autoimmune Registry Inc. (ARI) first comprehensive list of Autoimmune Diseases published in 2020, between 15 and 30 million people in the United States suffer from autoimmune disease, making it the nation's largest class of illness, and it primarily affects women aged 20 to 40. Therefore, increasing incidence of autoimmune diseases across the globe is driving the autoimmune disease diagnosis market. The high cost of diagnostic tests is a major challenge for the growth of the autoimmune disease diagnosis market. According to a survey by the National Adrenal Diseases Foundation (NADF), the cost for initial diagnosis of Addison’s disease is $1,680 per patient and according to the reports of Vasculitis Foundation of America, vasculitis affects 1 in 20 Americans and the total cost for vasculitis patient per year is $9.7 billion. According to the estimations of The National Institutes of Allergy and Infectious Diseases (NIAID), the annual cost of treating an autoimmune disease in the US is greater than $100 billion and says that annual direct and indirect cost to treat rheumatoid arthritis in the US is $10.9 billion and $8.4 billion respectively. The high cost of diagnosis is increasing the cost burdens on the patients impacting the growth of the autoimmune disease diagnosis market Biosensors and nano biosensors for rapid detection is a novel tool for the detection of antibodies in the autoimmune disease diagnosis market. They are highly preferred because of low cost, high sensitivity, simple to use, multiplexing abilities and rapid diagnosis. Besides measuring the quantity of antibodies in human blood serum with extremely high sensitivity, it also quantifies the activity of antibodies as the assay employs portable optical label-free biosensors based on the spectral correlation interferometry. This point of care technology gives a more integrated, informative, timely and precise diagnosis of autoimmune diseases when compared to the conventional ones. Major players in the autoimmune disease diagnosis market are Thermo Fisher Scientific, Siemens Healthineers, Abbott, Danaher, Bio-Rad Laboratories, Trinity Biotech, HYCOR Biomedical, EUROIMMUN AG, AESKU GROUP GMBH & CO. KG and F. Hoffmann-La Roche Ltd. North America was the largest region in the autoimmune disease diagnosis market in 2022. Western Europe was the second largest region in the global autoimmune disease diagnosis market. The regions covered in the global autoimmune disease diagnosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the autoimmune disease diagnosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The autoimmune disease diagnosis market includes revenue earned by diagnostic assay kits, reagents, consumables and instruments used for the diagnosis of autoimmune diseases. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global autoimmune disease diagnosis market is segmented - 1) By Product: Consumables & Assay Kits, Instruments 2) By Test Type: Routine Laboratory Tests, Autoantibodies Tests, Immunologic Tests, Other Tests 3) By End User: Clinical Laboratories, Hospitals, Other End Users

Benign prostatic hyperplasia or benign prostatic hypertrophy is a condition of prostate gland enlargement which causes blockade of urethra, the tube that carries urine from the bladder. The main products in the benign prostatic hyperplasia (BPH) treatment devices and equipment market are resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents, and implants. A resectoscope is an endoscope that is used for surgeries on the uterus, prostate, bladder, or urethra. The device helps in extracting tissue for biopsy, removing growths, or ablating diseased or damaged tissue. The various procedure types are transurethral needle ablation (TUNA), transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), transurethral microwave thermotherapy (TUMT), laser surgery, and others. The various end-users involved are hospitals, ambulatory surgical centres (ASC), clinics, homes. The benign prostatic hyperplasia (BPH) treatment market research report is one of a series of new reports from The Business Research Company that provides benign prostatic hyperplasia (BPH) treatment market statistics, including benign prostatic hyperplasia (BPH) treatment industry global market size, regional shares, competitors with a benign prostatic hyperplasia (BPH) treatment market share, detailed benign prostatic hyperplasia (BPH) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the benign prostatic hyperplasia (BPH) treatment industry. This benign prostatic hyperplasia (BPH) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global benign prostatic hyperplasia (BPH) treatment devices and equipment market size will grow from $1.49 billion in 2022 to $1.62 billion in 2023 at a compound annual growth rate (CAGR) of 8.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global benign prostatic hyperplasia (BPH) market size is expected to grow to $2.09 billion in 2027 at a CAGR of 6.6%. Benign Prostatic Hyperplasia (BPH) also called Prostate Gland Enlargement (PGE), is a condition where the patient suffers from uncomfortable urinary symptoms. Due to the rising prevalence of Benign Prostatic Hyperplasia (BPH), demand for the BPH treatment devices and equipment is on a steady rise as the number of BPH cases increases the demand for devices will also increase. For example, in 2021, more than 14 million men in the United States have symptoms of BPH. Globally 30 million men have symptoms related to BPH. Therefore, with the number of BPH cases on the steady rise, the demand for BPH treatment devices and equipment is also expected to grow. The side effects suffered by the patients after a BPH procedure are one of the major restraints for the BPH device and equipment market. For example, the most common side effects of a BPH surgery include urinary incontinence, discomfort during urination, and difficulty in completely emptying the bladder. The patients suffering from BPH do not prefer surgical procedures (till the stage it can be avoided) due to these side effects, therefore decreasing the demand for surgical procedures, which in turn limits the demand for devices used by end-users like hospitals, clinics, and ambulatory surgical centres. Prostatic Artery Embolization (PAE) is one of the latest developments in the market for Benign Prostatic Hyperplasia (BPH) treatment devices and equipment. PAE is a minimally invasive treatment that assists in reducing the symptoms observed in the urinary tract. The PAE procedure is done using X-rays and other advanced imaging to observe the tumor inside the body and accordingly treat it without any surgery. This technique results in reduced complications in the treatment of BPH and thus is said to be a major development in the market of BPH treatment. Leading companies such as Boston scientific, UNC healthcare, and Spire healthcare have been investing in the market for PAE Product recall is a process of retrieving all defective products that have been sold or are available in the market. When a company recalls a product from the market, the company bears all the cost of fixing the defective product and the cost of replacement. This cost of replacement for large companies can go up to a multi-million dollars, hence restraining the growth of the company and for the whole market as well. Product recall is one of the major hurdles for any market, Benign Prostatic Hyperplasia (BPH) Treatment Devices, and Equipment market is no exception. For example, in the year 2021, Arrow International recalled Arrow-Trerotola over-the-wire PTD kit percutaneous Thrombolytic device due the risk of separation. In March 2021, Olympus exercises, a Japan-based company manufacturer of optics and reprography products acquired Medi-Tate for an undisclosed amount. This acquisition of Medi-Tate to drive growth in its urology business and expand its minimally invasive treatment product portfolio. Medi-Tate is an Israeli medical device company for improves men's healthcare and quality of life through effective, non-surgical solutions. Major players in the benign prostatic hyperplasia (BPH) treatment devices and equipment market are Karl Storz, Lumenis, Olympus, Urologix, Boston Scientific Inc., Endo International, Neo tract, Lisa Laser, Medifocus Inc., ProArc Medical LTD., and Olympus America. North America was the largest region in the benign prostatic hyperplasia (BPH) treatment devices and equipment market in 2022. Western Europe was the second largest region in the global benign prostatic hyperplasia (BPH) treatment devices and equipment market. The regions covered in the global benign prostatic hyperplasia (BPH) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the benign prostatic hyperplasia (BPH) treatment devices and equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The benign prostatic hyperplasia (BPH) treatment devices and equipment market consist of sales of prostatic stents, catheter ablation devices, resectoscopes, radiofrequency ablation devices, urology lasers, and prostatic stents that are used to treat benign prostatic hyperplasia. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global benign prostatic hyperplasia (BPH) treatment devices and equipment market is segmented - 1) By Product: Resectoscopes, Radiofrequency Ablation Device, Urology Lasers, Prostatic Stents, Implants 2) By End-User: Hospitals, Ambulatory Surgical Centres (ASC), Clinics, Home 3) By Procedure Type: Transurethral Needle Ablation (TUNA), Transurethral Resection Of Prostate (TURP), Transurethral Incision Of Prostate (TUIP), Transurethral Microwave Thermotherapy (TUMT), Laser Surgery, Other Procedure Types

Fertility treatment is a medical treatment provided to a man or a woman to increase their chances of bearing an offspring. It is used to treat infertile patients. Hormone and ovulation-supporting medicines are frequently used in fertility treatments, sometimes in conjunction with minor surgical procedures. The main product types of fertility are reagents, and equipment. A reagent is a material or compound that is added to a system to produce a chemical reaction or to determine whether or not a reaction occurred. The treatments are performed on female and male in fertility clinics, hospitals, surgical centers, and clinical research institutes. The fertility treatment market research report is one of a series of new reports from The Business Research Company that provides fertility treatment market statistics, including fertility treatment industry global market size, regional shares, competitors with a fertility treatment market share, detailed fertility treatment market segments, market trends and opportunities, and any further data you may need to thrive in the fertility treatment industry. This fertility treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global fertility treatments market grew from $15.26 billion in 2022 to $16.48 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The fertility treatments market is expected to grow from $22.77 billion in 2027 at a CAGR of 8.4%. The growth in the median age of first-time motherhood combined with change in lifestyle increased the difficulty of conceiving, increasing the demand for fertility treatment. The median age of first-time motherhood has increased all over the globe due to late marriages, contraceptive techniques, and an increase in the number of women who prioritize their careers over starting a family. In 2020, the average age of first-time mothers in America has risen from 21 to 26. Women in other developed countries are also deferring, with the typical first birth occurring at the age of 31 for new mothers. In this scenario, a growing number of women are opting for IVF treatments, which is expected to drive this market. The high cost and low success rate of In vitro fertilization (IVF) treatment is a major factor that limits the growth of the fertility treatments market. In vitro fertilization is a fertilization process in which an egg is fertilized with sperm outside the body, in vitro. In vitro fertilization (IVF) treatment costs differ in many countries due to the lack of refund policies. Moreover, insurance companies usually do not cover infertility treatments. According to the American society of reproductive medicine, in the USA, the average cost of an IVF cycle is $12,400 and the average cost of an IVF cycle using fresh embryos is $8,158 with a median cost at $7,500. The rate of success of IVF treatments is only 28% to 35%, which decreases with the increase in woman's age. For example, for women, the success rate is 32.2% under 35 and 1.9% for women aged over 44. Thus, the high cost and low success rate of IVF treatment restrict the growth of the fertility treatment market. Development of new techniques to treat infertility using a human’s body is a key trend in the fertility treatments market. INVOcell is an IVF alternative that uses the woman’s body to support fertilization, thus eliminating the cost of a laboratory incubator. The INVOcell device is placed with the eggs and sperm in the vaginal cavity, allowing for the stability of the natural environment, pH, and gas to help in fertilization. INVOcell, which is made in Medford, Massachusetts by INVO Bioscience, costs around $6,800 including medication. Although IVF generated more quality embryos, the birth rates between IVF and INVOcell are similar. According to the journal of assisted reproduction and genetics, 12 out of 20 women gave birth to 15 babies in IVF including three sets of twins and 11 out of 20 women gave birth to 16 babies in INVOcell group including five sets of twins. In August 2022, CCRM Fertlity, an American fertility treatment company, acquired Institute for Reproductive Medicine & Sciences (IRMS) for an undisclosed amount. The acquisition would add world class proprietary reproductive medicine offerings to the CCRM’s portfolio and expand its footprint across 11 major metropolitan areas with 34 locations across the US and Canada. Institute for Reproductive Medicine and Science (IRMS) is a US-based fertility research and treatment company having its presence in major metropolitan areas. Major players in the fertility treatment market are Apollo Hospitals Enterprise Ltd., Care Fertility Group, Genea Limited, The Johns Hopkins Health System Corp., Medicover Group, Monash IVF Group, Progyny Inc., Vitrolife, Carolinas Fertility Institute, OvaScience Inc., Xytex Cryo International, Merck KGaA, Cook Medical, CooperSurgical Inc., Instituto Bernabeu, INVO Bioscience, The Cooper Companies Inc., Virtus Health, CryoChoice LLC., Millendo Therapeutics Inc., FUJIFILM Irvine Scientific, LABOTECT GMBH, Fertility Focus, Olympus Corporation, Irvine Scientific sales Company Inc., and Ferring Pharmaceuticals. North America was the largest region in the fertility treatment market in 2022. Western Europe was the second largest region in the global fertility treatment market. The regions covered in the global fertility treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the fertility treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The fertility treatment market includes revenues earned by entities by providing medicinal services, surgical services, and assisted services such as in vitro fertilization. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global fertility treatments market is segmented - 1) By Product: Reagents, Equipment 2) By End-User: Fertility Clinics, Hospitals, Surgical Centers, Clinical Research Institutes 3) By Patient Type: Female, Male

Polycystic ovarian syndrome is a disorder in which hormones are out of control for females and they have male hormones that are higher than normal, which causes them to skip menstrual periods and makes pregnancy more difficult for them. The main drug types in the polycystic ovarian syndrome treatment market are oral contraceptives, ornithine decarboxylase inhibitors, insulin-sensitizing agents, anti-depressants, diuretics, and aromatase inhibitors. Oral contraceptives are hormone-based drugs that are taken orally to prevent pregnancy. They prevent pregnancy by slowing ovulation and preventing sperm from entering the cervix. The various surgery types include ovarian wedge resection and laparoscopic ovarian drilling, which are performed in hospitals and clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, and feminist health centers. The polycystic ovarian syndrome treatment market research report is one of a series of new reports from The Business Research Company that provides polycystic ovarian syndrome treatment market statistics, including polycystic ovarian syndrome treatment industry global market size, regional shares, competitors with a polycystic ovarian syndrome treatment market share, detailed polycystic ovarian syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the polycystic ovarian syndrome treatment industry. This polycystic ovarian syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global polycystic ovarian syndrome treatment market will grow from $4.26 billion in 2022 to $4.49 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global polycystic ovarian syndrome treatment market is expected to grow to $5.66 billion in 2027 at a CAGR of 5.9%. The global rise in genetic and hormonal disorders is a key factor driving the growth of the polycystic ovarian syndrome (PCOS) treatment market. PCOS is a prevalent hormonal disorder among premenopausal women worldwide, with reproductive, endocrine, and metabolic abnormalities. The PCOS prevalence ranges from 2.2% to 26% globally and is highly variable. In China, the figures range between 2% to 7.5% and 6.3% in Sri Lanka, 9.13% in south India and 22.5% in Maharashtra. The rise in genetic and hormonal disorders globally is expected to increase the growth of the polycystic ovarian syndrome treatment market. Lack of drugs approved by regulatory bodies such as FDA (Food and Drug Administration) among many countries is a key factor hampering the growth of the polycystic ovarian syndrome treatment market. FDA has not approved pharmacological treatment for use in adolescents with PCOS. However, some pharmacological interventions are used to treat PCOS symptoms. For instance, rimonabant, a key appetite suppressant cannabinoid CB1 receptor antagonist was not approved by the United States Food and Drug Administration (FDA) in the USA due to concerns about suicidal ideation and drug overdoses. Moreover, Minoxidil is the only drug approved by FDA, used for the treatment of female pattern baldness. Therefore, the lack of regulatory body approved drugs in many countries is a key factor restraining the growth of the polycystic ovarian syndrome treatment market. Laparoscopic ovarian drilling is a major trend driving the growth of the polycystic ovarian syndrome treatment market. Laparoscopic ovarian drilling is a surgical treatment performed by doctors in critical conditions that can cause ovulation in women with polycystic ovary syndrome (PCOS). Ovarian drilling is often used by women with PCOS who often do not ovulate despite having attempted weight loss and the use of fertility drugs. According to a 2021 study published on Taylor and Francis online, an American open access journal, the efficacy of ovarian drilling was variable in different literature. Ovulation and pregnancy rates were found to be 30%-90% and 13%-80% respectively. In December 2021, Organon& Co., an American pharmaceutical company working to improve women’s health, acquired Forendo Pharma for $954 million. Through this acquisition Organon plans to bring innovation in the area of women’s health and develop better treatments. Forendo Pharma is a Finland-based clinical stage pharmaceutical company pioneering in the areas of intracrinology and polycystic ovarian syndrome (PCOS). Major players in the polycystic ovarian syndrome treatment market are Bristol-Myer Squibb Company, Bayer AG, Pfizer Inc., Merck KGaA, Sanofi, AstraZeneca, Novartis AG, Teva Pharmaceutical Industries Limited, Abbott, Addex Therapeutics Ltd., BIOCAD, Allergan PLC., Johnson and Johnson, Ferring BV, and Ferring Pharmaceuticals Inc. North America was the largest region in the polycystic ovarian syndrome treatment market in 2022. Western Europe was the second largest region in the global polycystic ovarian syndrome treatment market. The regions covered in the global polycystic ovarian syndrome treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the polycystic ovarian syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The polycystic ovarian syndrome treatment market includes revenue earned by first line drugs for treating hirustism, first line drugs for ovulation, and insulin sensitizing drugs. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global polycystic ovarian syndrome treatment market is segmented - 1) By Drug Type: Oral Contraceptives, Ornithine Decarboxylase Inhibitors, Insulin-Sensitizing Agents, Anti-Depressants, Diuretics, Aromatase Inhibitors 2) By Surgery Type: Ovarian Wedge Resection, Laparoscopic Ovarian Drilling 3) By End User: Hospitals & Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Gynecology Centers, Feminist Health Centers

Neutropenia biologic drug treatment refers to drugs that are used to reduce fevers or potential infections as well as activate the bone marrow and boost neutrophil production. A lack of neutrophils, a particular type of white blood cell, causes neutropenia. The main types of drugs in neutropenia biologic drug treatment are filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim, and sargramostim. Filgrastim is a recombinant form of granulocyte colony-stimulating protein that is given as an injection to boost neutrophil production after chemotherapy. The different types of treatments include antibiotic drugs, granulocyte-colony-stimulating factor (G-CSF), antifungal drugs, and others, and are distributed through various channels such as retail pharmacies, hospital pharmacies, and online pharmacies. The neutropenia biologic drug treatment market research report is one of a series of new reports from The Business Research Company that provides neutropenia biologic drug treatment market statistics, including global market size, regional shares, competitors with a neutropenia biologic drug treatment market share, detailed neutropenia biologic drug treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neutropenia biologic drug treatment industry. This neutropenia biologic drug treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global neutropenia biologic drug treatment market grew from $11.26 billion in 2022 to $12.29 billion in 2023 at a compound annual growth rate (CAGR) of 9.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The neutropenia biologic drug treatment market is expected to grow from $15.79 billion in 2027 at a CAGR of 6.5%. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the market for neutropenia biologic drugs. Due to a growing cancer incidence and an increase in the number of people opting for chemotherapy, there has been an increase in the number of people suffering from neutropenia. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. Therefore, the rise in cancer incidence rates globally is anticipated to boost demand for the neutropenia biologic drug treatment market over the forthcoming years. The introduction of biosimilars as a result of patent expiry is expected to hamper the growth of the neutropenia biologic drug treatment market. Biosimilar is a therapeutic agent that has high similarity with the original biological product in action but is available at a lower cost than the original product. Biosimilars are mostly priced at 70% of the price of branded drugs and are likely to replace expensive branded drugs. For instance, in May 2022, Biocon Biologics Limited, an India-based biopharmaceutical company specialising in the development of biological drugs, launched Abevmy® (bBevacizumab) in collaboration with Viatris Inc., a US-based healthcare and biopharmaceutical company pioneering in the development of medicines, advancing sustainable operations, and developing innovative solutions. Abevmy® (bBevacizumab) is being developed to treat various types of cancer, including solid tumors. Companies in the neutropenia biologic drug treatment market are increasingly investing in developing novel drug delivery systems to improve the therapeutic response of the drug and increase its efficacy. Novel drug delivery systems allow the delivery of a very high dose of drugs directly into the neutrophils, while the systemic dose remains low, thus disabling side effects. For instance, in August 2020, Asalyxa Bio announced its formation and seed funding to accelerate ASX-100 into first-in-human trials in 2021. ASX-100 is a novel spherical particle that releases a safe and effective anti-inflammatory agent, salicylic acid, directly to over-reactive immune cells and is used for treating severe neutrophil-mediated disease. In September 2020, Gilead Sciences, a US-based biopharmaceutical company, launched Immunomedics for $21 billion. Through this acquisition, Gilead will get TrodelvyTM ( acituzumabgovitecan-hziy), which will alter Gilead’s portfolio by adding a first-in-class commercial drug with considerable revenue potential and best-in-class potential. Immunomedics is a biotechnology company based in the United States that provides biologic drug treatment for neutropenia. Major players in the neutropenia biologic drug treatment market are Teva Pharmaceutical, Amgen, Sanofi, Mylan, Kyowa Kirin, Baxter International, CVS Health Corp., Novartis, Spectrum Pharmaceuticals, and Partner Therapeutics. North America was the largest region in the neutropenia biologic drug treatment market in 2022. The regions covered in the global neutropenia biologic drug treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the neutropenia biologic drug treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The neutropenia biologic drug treatment market consists of sales of cefepime, ceftazidime, piperacillin-tazobactam, and meropenem. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global neutropenia biologic drug treatment market is segmented - 1) By Drug Type: Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim 2) By Treatment Type: Antibiotic Drugs, Granulocyte-Colony-Stimulating Factor (G-CSF), Antifungal Drugs, Other Treatment Types 3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies

Psoriatic arthritis treatment refers to a method of treatment or drug used to stop or lessen a chronic inflammatory disease of the joints and the areas where tendons and ligaments attach to the bones (entheses). This treatment focuses on controlling skin involvement and treating joint pain and disability. The main classes of drugs in psoriatic arthritis treatment are nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), biologics, and others. A biologic medicine (biologics) is a substance that is made from or contains living organism components.The different routes of administration include oral, parenteral, and topical, and they are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies. The psoriatic arthritis treatment market research report is one of a series of new reports from The Business Research Company that provides psoriatic arthritis treatment market statistics, including global market size, regional shares, competitors with a psoriatic arthritis treatment market share, detailed psoriatic arthritis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the psoriatic arthritis treatment industry. This psoriatic arthritis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global psoriatic arthritis treatment market grew from $8.92 billion in 2022 to $9.94 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The psoriatic arthritis treatment market is expected to grow from $14.36 billion in 2027 at a CAGR of 9.6%. The rise in the prevalence of psoriasis and psoriatic arthritis boosted the growth of the psoriatic arthritis treatment market. Psoriasis (PSO) and psoriatic arthritis (PsA) are inflammatory disorders that can severely impair health and quality of life. Psoriasis is associated with inflammatory arthritis, known as psoriatic arthritis (PsA), with an incidence of 30% in psoriatic patients. For instance, in June 2021, according to the National Psoriasis Foundation, a US-based healthcare agency, more than 8 million people in the United States and 125 million people worldwide suffered from psoriasis, a chronic immune-mediated illness. Furthermore, in the USA, about 30% of people with psoriasis also develop psoriatic arthritis. Thus, an increase in the prevalence of psoriasis and psoriatic arthritis drives market growth. The development of novel drugs such as Janus kinase (JAK) inhibitors for treating psoriatic arthritis is shaping the market. Janus kinase (JAK) inhibitors are orally administered small molecules that are emerging as a novel treatment for psoriatic arthritis patients. There are three JAK inhibitors approved for the treatment of autoimmune diseases: tofacitinib, baricitinib, and upadacitinib. Among them, Xeljanz (tofacitinib) and Xeljanz (tofacitinib) XR are the first Janus kinase (JAK) inhibitors that have been approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). They are used to treat adult patients with active psoriatic arthritis (PsA), who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs). In June 2020, AbbVie, a leading US-based pharmaceutical company, announced that it had applied for the approval of upadacitinib (RINVOQ), a JAK inhibitor, with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Amgen Inc., an American biopharmaceutical company headquartered in Thousand Oaks, California, acquired Celgene’s Otezla for $13.4 billion. Otezla supports Amgen’s mission to bring innovative medicines to patients and expand its product portfolio. Amgen also gets worldwide rights with Otezla's acquisition. Otezla (apremilast) is indicated for the treatment of patients with moderate to severe plaque psoriasis and active psoriatic arthritis. Celgene Corporation is a US-based biopharmaceutical company, acquired by Bristol-Myers Squibb Company, that develops and markets drugs used in the treatment of cancer and anti-inflammatory diseases. Major players in the psoriatic arthritis treatment market are AbbVie, Amgen, Johnson & Johnson, Bristol-Myers Squibb Company, Celgene Corporation, Novartis, Eli Lilly and Company, Pfizer, UCB Biosciences Inc., and Hoffmann La Roche Ltd. North America was the largest region in the psoriatic arthritis treatment market in 2022. The regions covered in the global psoriatic arthritis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the psoriatic arthritis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The psoriatic arthritis treatment market includes revenues earned by entities by reducing pain and swelling and controlling inflammation and pain. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global psoriatic arthritis treatment market is segmented - 1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biologics, Other Drug Classes 2) By Route Of Administration: Oral, Parenteral, Topical 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Macula refers to the central portion of the retina, a light-sensitive layer of tissue at the back of the eye. The macula is responsible for central vision. Degeneration of the macula, which affects the central part of the retina (the macula) and results in distortion or loss of central vision, occurs most commonly after the age of 60 and is referred to as age-related macular generation (AMD). The macular degeneration treatment is used to treat macular degeneration eye disease and slow the disease and prevent severe loss of vision. The main disease stages in the macular degeneration treatment market are early-stage AMD, intermediate AMD, and late-stage AMD. In early-stage AMD, the macula changes, with medium-sized drusen deposits and no pigment changes, but this does not impact vision. Intermediate AMD is when vision may get blurry or wavy with large drusen or pigment changes. In late-stage AMD, the central vision fails completely, causing vision loss. The different types of macular degeneration treatments include wet macular degeneration and dry macular degeneration. The different routes of administration of macular degeneration treatment include oral, injectable, and others used by different end-users such as ambulatory surgical centers, ophthalmic clinics, and hospitals. The macular degeneration treatment research report is one of a series of new reports from The Business Research Company that provides macular degeneration treatment statistics, including macular degeneration treatment industry global market size, regional shares, competitors with macular degeneration treatment shares, detailed macular degeneration treatment segments, market trends and opportunities, and any further data you may need to thrive in the macular degeneration treatment industry. This macular degeneration treatment research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global macular degeneration treatment market size grew from $8.44 billion in 2022 to $9.43 billion in 2023 at a compound annual growth rate (CAGR) of 11.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The macular degeneration treatment market size is expected to grow to $14.3 billion in 2027 at a CAGR of 11.0%. The increasing burden of retinal disorders is expected to propel the growth of the macular degeneration treatment market. Retinal disorders affect the vital tissue and affect the way individuals process visual information, leading to distorted or absent vision. According to a study done in Tanzania in 2020 about the prevalence of retinal diseases and associated risk factors, out of 1,007 people, the prevalence of vitreoretinal disorders was 22.8% (230/1,007). The study was conducted by OSLI Retina, which focuses solely on retinal diseases, surgery, and pharmacotherapy. The leading retinal diseases were age-related hypertensive macular scars (2.7%), retinopathy (4.5%), and degeneration (7.0%). According to the American Academy of Opthalmology, in 2050, an estimated 7.32 million people in the United States will have primary open-angle glaucoma, with the highest numbers among populations aged 70 to 79 years (32%), women (50%), and Hispanics (50%). The largest demographic group is Hispanic men. Therefore, the increasing burden of retinal disorders is driving the growth of the macular degeneration treatment market. The development of advanced therapies is a key trend gaining popularity in the macular degeneration treatment market. Advanced therapy, including gene therapy, for the treatment of disease has seen development in recent years, particularly in the world of inherited retinal disease. For instance, in October 2021, Genentech, a US-based biotechnology company, announced that FDA has approved Susvimo, a new treatment for wet age-related macular degeneration. Susvimo is the first wet AMD treatment to offer an alternative to the standard-of-care eye injections required as frequently as once per month in the last 15 years. Susvimo will help people with wet AMD retain their vision with as few as two treatments per year by continually injecting medication into the eye via a refillable implant. In September 2021, Novartis, a Swiss-based pharmaceutical company, acquired Arctos Medical for an undisclosed amount. The acquisition is expected to allow Novartis to find treatments for patients with vision loss and leverage the potential of optogenetics as the basis of successful therapeutics. Arctos Medical is a Switzerland-based developer of smart medical devices and gene therapy approaches for ophthalmological diseases for treating blindness. Major players in the macular degeneration treatment market are Novartis AG, Bausch Health Companies Inc., Regenxbio Inc., F Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., GlaxoSmithKline plc, Bayer AG, Neurotech Pharmaceuticals Inc., Ophthotech Corporation, StemCells Inc., Pfizer Inc., Santen Pharmaceuticals, Alimera Sciences Inc., Aerie Pharmaceutical Inc., Panoptica, Allergan Inc., Valeant Pharmaceuticals, and Rxi Pharmaceuticals Inc. In 2022, North America will be the largest region in the macular degeneration treatment market. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the macular degeneration treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the Macular Degeneration Treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The macular degeneration treatment market includes revenues earned by entities by anti-angiogenic drugs, photodynamic therapy, laser therapy and low vision aids. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global macular degeneration treatment market is segmented - 1) By Stage of Disease: Early-Stage AMD, Intermediate AMD, Late-Stage AMD 2) By End User: Ambulatory Surgical Centers, Ophthalmic Clinics, Hospitals 3) By Route of Administration: Oral, Injectable, Other Route of Administration 4) By Types: Wet Macular Degeneration, Dry Macular Degeneration

Hyperphosphatemia treatment refers to a class of drug that boosts renal excretion to treat patients' hyperphosphatemia. The most efficient way to do this is through volume replenishment with saline and forced diuresis with a loop diuretic like furosemide or bumetanide. The main products in the hyperphosphatemia treatment market are sevelamer, calcium-based phosphate binders, iron-based phosphate binders, lanthanum carbonate, and others. The sevelamer market consists of sales of sevelamer products by entities (organisations, partnerships, and sole traders) that refer to phosphate binding medication used for the treatment of hyperphosphatemia in patients with chronic and kidney diseases. The hyperphosphatemia treatment is distributed through hospital pharmacies, retail pharmacies, and online stores. By dosage form, it is segmented into capsules, tablets, and syrups. The hyperphosphatemia treatment market research report is one of a series of new reports from The Business Research Company that provides hyperphosphatemia treatment market statistics, including hyperphosphatemia treatment industry global market size, regional shares, competitors with a hyperphosphatemia treatment market share, detailed hyperphosphatemia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the hyperphosphatemia treatment industry. This hyperphosphatemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hyperphosphatemia treatment market size grew from $3.57 billion in 2022 to $3.98 billion in 2023 at a compound annual growth rate (CAGR) of 11.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hyperphosphatemia treatment market size is expected to grow to $6.27 billion in 2027 at a CAGR of 12.1%. The increase chronic diseases among patients is driving the growth of the hyperphosphatemia treatment market. Chronic diseases are non-communicable and require long-term care. A vast majority of chronic diseases can be categorised as cardiovascular diseases, chronic kidney disease, chronic respiratory conditions, hyperparathyroidism, diabetes, and cancer. According to the World Health Organization (WHO), chronic disease prevalence is predicted to increase by 57% by the year 2020. According to the United States, the Renal Data System estimates that there are more than 300,000 patients with end-stage renal disease in the United States. There has been an increase in hyperphosphatemia among patients with end-stage renal disease (ESRD), thus contributing to an increase in demand for hyperphosphatemia treatment or drugs. The increasing research and development activities are a key trend in the hyperphosphatemia treatment market. The company in hyperphosphatemia treatment are focused on research and development activities for the development of innovative therapies for the treatment of renal diseases and related chronic conditions. For instance, in May 2021, Alebund Pharmaceuticals, a Shanghai-based biopharmaceutical company, raised $60 million in a Series B round to accelerate its development activities of innovative drugs and solutions for the treatment of renal diseases, including hyperphosphatemia. In December 2020, Unicycive, a US-based company that develops novel treatments across multiple therapeutic areas, acquired Renazorb for an undisclosed amount. This acquisition will help Renazorb rapidly develop an alternate treatment for hyperphosphatemia supported by an extended history of the utilisation of lanthanum compounds for phosphate binding but with a potential to significantly enhance simple dosing and thereby improve patient adherence. Renazorb is a US-based company that's a non-aluminium, non-calcium, phosphate binder manufactured employing a patent-protected nanotechnology process. Major players in the hyperphosphatemia treatment market are Sanofi, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Akebia Therapeutics, Inc., Vifor Pharma Management Ltd., Lupin Limited, Ardelyx, Inc., Unicycive Therapeutics, Inc., Keryx Biopharmaceuticals, Zeria Pharmaceutical, Fresenius Medical Care, Shire, Ultragenyx Pharmaceutical, Inc., Sun Pharmaceutical Industries, Ltd., Akebia Therapeutics, Inc., and AMAG Pharmaceuticals, Inc., North America was the largest region in the hyperphosphatemia treatment market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hyperphosphatemia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the Hyperphosphatemia Treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The hyperphosphatemia treatment market includes revenues earned by lowering the phosphate load and maintaining serum phosphorus levels within the normal range. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global hyperphosphatemia treatment market is segmented - 1) By Product: Sevelamer, Calcium-Based Phosphate Binders, Iron-Based Phosphate Binders, Lanthanum Carbonate, Other products 2) By Distribution channel: Hospital Pharmacy, Retail Pharmacy, Online stores